Effectiveness and Treatment Patterns in Patients With First-Line 2G ALK TKI Across the ESME French Real-World Cohort
Girard N, Eltaief S, Debieuvre D, Le Guen Y, Le H, Rifi N, Audigier-Valette C, Remon J, Bosquet L, Chouaid C, Pérol M
WCLC 2025
- 世界肺癌大会 2025
| 肿瘤 | 肺癌 | 博瑞纳
Biomarker Analysis and Final Efficacy of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Bauer TM, Martini J-F, Besse B, Lin C-C, Soo RA, Riely GJ, Toffalorio F, Shepard DA, Liang S-Y, Hamilton P, Camidge DR, Kao S, Chiari R, Gadgeel S, Felip E, Shaw AT, Solomon BJ
WCLC 2025
- 世界肺癌大会 2025
| 肿瘤 | 肺癌 | 博瑞纳
Optimizing Treatment Sequencing to Maximize Survival in ALK+ Advanced Non-Small Cell Lung Cancer: A Modeling Study
Le H, Rifi N, Williams T, Bloudek L, Ramsey S
WCLC 2025
- 世界肺癌大会 2025
| 肿瘤 | 肺癌 | 博瑞纳
A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non–Small Cell Lung Cancer: A Patient-Centered Approach
Stinchcombe TE, Leblanc TW, Culver KW, Reiss M, Coulter J, Peay HL, Poulos C, Moultrie R, Potter S, Bussberg C, Vass C, Rifi N, Krulewicz S, Brown L, Le H
WCLC 2025
- 世界肺癌大会 2025
| 肿瘤 | 肺癌 | 博瑞纳
